Arcutis Biotherapeutics, Inc. (ARQT) has experienced a remarkable surge in its stock value following an impressive financial performance in Q3 2025 and a positive revenue forecast for FY 2026. At the heart of this growth is Zoryve, a leading product in the dermatology sector, which continues to expand its reach and market impact. The company's strategic focus on non-steroidal treatments positions it for sustained success and substantial financial returns.
Soaring Prospects: Arcutis Biotherapeutics on a Growth Trajectory
Zoryve's Market Dominance and Expanding Applications
Shares of Arcutis Biotherapeutics, a prominent name in dermatology biopharmaceuticals, saw a significant increase of 27%, reaching a 38-month high of $24.95. This surge was driven by an outstanding Q3 2025 earnings report and an encouraging initial sales guidance for FY 2026. Zoryve, a versatile product in the company's portfolio, is rapidly gaining traction. It has secured six approvals across three different indications, leading to a substantial increase in revenue. This expansion highlights Zoryve's growing acceptance and effectiveness in the medical community, particularly as healthcare providers increasingly favor alternatives to traditional steroid-based treatments.
